Article Text
PDF
Abstract
Among biomedical journals, person-first language is considered preferable to identity person-first language. However, not all populations of people with certain medical diagnoses, such as deafness, prefer person-first language. Moreover, adherence to person-first language is poor among the literature on some neurological diagnoses. Therefore, it is most appropriate to consult with people with a given diagnosis regarding their preferred identifier. Here, we describe a consensus process undertaken by the REsearch objectives and COmmon Data Elements for Degenerative Cervical Myelopathy (RECODE-DCM, recode-dcm.com) steering committee members with cervical myelopathy to determine our preferred identifier.
- attitudes
- patient advocacy
- patient preference
This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
Statistics from Altmetric.com
The choice of language is important for effective communication, especially in healthcare. However, language by itself, for example, to denominate a group, can impact health outcomes.1
‘Person-first’ or ‘person-centred’ language refers to communication that acknowledges the individual first, followed by a descriptor of the condition or disability. It contrasts with ‘identity-first’ and/or ‘disease-first’ language, which highlight the condition.
Person-first language is advocated by many leading healthcare organisations, particularly in the context of disabilities, such as the National Institute for Health and Care Excellence (UK).2 However, certain groups, such as the ‘deaf’ community, prefer identity-first terminology, as they consider deafness a description and not a disability.3
Consequently, as part of AOSpine RECODE-DCM (www.recode-dcm.com), an international, multistakeholder consensus project to improve research efficiency we sought to confirm an appropriate identifier. This was left at the discretion of the eight members with DCM (six female, average age 56 and length of symptoms 6 years). Terms were suggested and/or opposed via email correspondence (summarised in table 1). Discussion quickly focused on person-first language, with eventual unopposed consensus for ‘Person with Cervical Myelopathy’. The term degenerative was dropped, but cervical retained, in order to offer a more concise description with sufficient specificity. The term was agreed by the full steering committee and adopted for AOSpine RECODE-DCM.
Terms suggested by committee members with cervical myelopathy (n=8)
The readiness to adopt person-first language appears variable,1 particularly in the scientific literature.3 This is despite its inclusion in numerous scientific style guides, including the American Medical Association Manual of Style.4 For example, despite the fact that persons with multiple sclerosis have adopted person-first language, of the 50 most highly cited papers of the past 5 years from Web of Science (Clarivate Analytics, USA), only 44% used person-first language.
The reason for this is unclear. However, it was interesting to note that despite our prior agreements, professionals drafting articles for early objectives of AOSpine RECODE-DCM, inadvertently returned to referring to individuals by their diagnosis or disability rather than using person-first language.
This topic has received contrasting commentary over the last 20 years.5 However, in an era of increasing user engagement in research design, conduct and consumption, we encourage community consultation on terminology and its consistent adoption, not just in ‘patient’ conversation, but throughout practice and research.
This is now the case for AOSpine RECODE-DCM.
Acknowledgments
The authors would also like to acknowledge the rest of the RECODE-DCM Steering committee including: Evangeline 'Paige' Howard, Delphine Houghton, Julia Carter, Margot Miller, Jillian Polasik, Shirley Widdop, Theresa Brislin, Carla Salzman, Lindsay Tetreault, Michelle L. Starkey, Geno J Merli, Katherine Palmieri, Bizhan Aarabi, James Harrop, Jefferson R Wilson, Angus G.K. McNair, Sukhvinder Kalsi-Ryan, Robert Chen, James Milligan, Julio C Furlan, Vafa Rahimi-Movaghar, Brian K Kwon, Shekar N Kurpad, James D Guest, Michael G.
Footnotes
Twitter @iwansadler
Collaborators RECODE-DCM Steering Committee:Evangeline 'Paige' Howard, Delphine Houghton, Julia Carter, Margot Miller, Jillian Polasik, Shirley Widdop, Theresa Brislin, Carla Salzman, Lindsay Tetreault, Michelle L. Starkey, Geno J Merli, Katherine Palmieri., Bizhan Aarabi, James Harrop, Jefferson R Wilson, Angus G.K. McNair, Sukhvinder Kalsi-Ryan, Robert Chen, James Milligan, Julio C Furlan, Vafa Rahimi-Movaghar, Brian K Kwon, Shekar N Kurpad, James D Guest, Michael G. Fehlings, Armin Curt.
Contributors TFB: data collection, conceptualisation, manuscript review and preparation. IS: manuscript review and preparation. ES: manuscript review and preparation. BMD: conceptualisation, manuscript review and preparation. MRNK: manuscript review and conceptualisation. RECODE-DCM: manuscript review and preparation
Funding Research in the senior author’s laboratory is supported by a core support grant from the Wellcome Trust and MRC to the Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute. MRNK is supported by a NIHR Clinician Scientist Award. This report is independent research arising from a Clinician Scientist Award, CS-2015-15-023, supported by the National Institute for Health Research. TFB was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, Award Number TL1TR001437.
Disclaimer The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care. The content is solely the responsibility of the author(s) and does not necessarily represent the official views of the NIH.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information:
Other content recommended for you
- Developing common demographic data elements to include in future editions of the SCAT and Child SCAT: a modified international Delphi study
- A core set of trial outcomes for every medical discipline
- Frailty measurement and outcomes in interventional studies: protocol for a systematic review of randomised control trials
- Real world effectiveness of primary implantable cardioverter defibrillators implanted during hospital admissions for exacerbation of heart failure or other acute co-morbidities: cohort study of older patients with heart failure
- Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume II — practical challenges
- Treatment options in idiopathic subglottic stenosis: protocol for a prospective international multicentre pragmatic trial
- Western Regional Meeting Abstracts
- International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis
- Genomic Centers for Infectious Diseases (U19): RFA - AI-13-009
- Protocol for the mixed - methods development of a concussion - specific health - related quality of life outcome measure based on the international classification of functioning, disability and health